Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Devextinetug - InterveXion Therapeutics

Next Previous
Search
Drug Profile

Devextinetug - InterveXion Therapeutics

Alternative Names: Anti-methamphetamine chimeric monoclonal antibody - InterveXion Therapeutics; Anti-methamphetamine monoclonal antibody; Ch-mAb7F9; IXT-m200; METH-mAb

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Arkansas for Medical Sciences
  • Developer InterveXion Therapeutics
  • Class Drug withdrawal therapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Substance-related disorders

Most Recent Events

  • 07 Nov 2023 InterveXion Therapeutics and the National Institute on Drug Abuse terminates a phase II trial in Substance related disorders in USA due to interim analysis concluded planned study numbers combined with participant dropout rates were insufficient to meet primary endpoint (IV) (NCT05034874)
  • 20 Jul 2023 Efficacy and adverse events data from a phase II Meth-OD trial in Substance-related disorders released by InterveXion Therapeutics
  • 05 Jan 2023 InterveXion Therapeutics terminates a phase II Meth-OD trial in Substance-related disorders in USA (IV) (NCT04715230)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top